NADH disodium salt (Disodium NADH) 是一种口服有效的还原型辅酶。NADH disodium salt 还是 ADP-核糖基转移酶反应中的 ADP-核糖单元的供体和环状 ADP-核糖的前体。NADH disodium salt 在细胞的能量代谢过程中起到再生电子供体的作用，包括糖酵解，β-氧化和三羧酸 (TCA) 循环。
| 生物活性 | NADH disodium salt (Disodium NADH) is an orally active reduced coenzyme. NADH disodium salt is a donor of ADP-ribose units in ADP-ribosylaton reactions and a precursor of cyclic ADP-ribose. NADH disodium salt plays a role as a regenerative electron donor in cellular energy metabolism, including glycolysis, β-oxidation and the tricarboxylic acid (TCA) cycle[1]. |
| IC50& Target | Human Endogenous Metabolite |
|
体外研究
(In Vitro) | NADH is unstable under acidic conditions but it is stable under alkaline conditions[2].
NADH (0-1 mM; 0-12 h) increases NAD+levels in various mammalian cell lines[3].
NADH (1 mM; 24 h) causes low toxicity and protects cells from genotoxicity[3].
|
体内研究
(In Vivo) | NADH (5 μmol/mouse; i.p.; once) increases urinary excretion of nicotinamide and its metabolites in mice[2].
NADH (500 mg/kg; i.g.; once) promotes alcohol metabolism and prevents or ameliorates early liver injury caused by acute alcohol exposure in ethanol-loaded mice[3].
NADH (1000 mg/kg; i.p.; once) enhances tissue NAD+levels in male C57BL/6J mice[3].
| Animal Model: | Male ICR mice[2] | | Dosage: | 5 μmol/mouse | | Administration: | Intraperitoneal injection or oral administration, once | | Result: | Produced significant increases in urinary excretions of nicotinamide (Nam) with intraperitoneal injection. Oral administration did not produce any increases in Nam or its metabolites. |
| Animal Model: | Male C57BL/6J mice[3] | | Dosage: | 500 mg/kg | | Administration: | Intragastric administration, 15 min before ethanol administration | | Result: | Significantly increased blood acetaldehyde levels in mice administered with alcohol between 30 min and two hours. Significantly reduced the acetaldehyde in the blood after two hours. Inhibited the decrease of NAD+/NADH redox ratio in hepatocytes. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 结构分类 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| 溶解性数据 | In Vitro: H2O : ≥ 100 mg/mL(140.96 mM) DMSO : 100 mg/mL(140.96 mM;Need ultrasonic) *"≥" means soluble, but saturation unknown. 配制储备液 | 1 mM | 1.4096 mL | 7.0482 mL | 14.0964 mL | | 5 mM | 0.2819 mL | 1.4096 mL | 2.8193 mL | | 10 mM | 0.1410 mL | 0.7048 mL | 1.4096 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： PBS Solubility: 100 mg/mL (140.96 mM); Clear solution; Need ultrasonic 2. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: 2.5 mg/mL (3.52 mM); Clear solution; Need ultrasonic
此方案可获得 2.5 mg/mL (3.52 mM) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 3. 请依序添加每种溶剂： 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: 2.5 mg/mL (3.52 mM); Clear solution; Need ultrasonic
此方案可获得 2.5 mg/mL (3.52 mM) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
